Press release
Amyloidosis Therapeutics Market Size Anticipated to Reach USD 6.3 Billion by 2034, Growing at a CAGR of 6.5% - Transparency Market Research
Amyloidosis Therapeutics Market
The market expansion is being fueled by a combination of increased disease awareness, improved treatment options, and significant investments in drug discovery. As pharmaceutical companies and biotechnology firms continue to introduce novel therapies, the industry is poised for rapid advancements that will improve patient outcomes and expand treatment accessibility.
Access important conclusions and data points from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86469
The Amyloidosis Therapeutics Market is set to experience significant growth in the coming years, driven by the increasing prevalence of amyloidosis, advancements in drug development, and rising investments in research and development (R&D). Amyloidosis is a serious condition in which abnormal proteins, known as amyloids, accumulate in organs and tissues, leading to dysfunction. While it remains a rare disease, improved diagnostic capabilities and growing awareness are enabling early detection and better treatment options.
Key Market Growth Drivers and Emerging Trends
Increasing Prevalence of Amyloidosis Driving Market Expansion
The growing number of light-chain amyloidosis (AL) cases and other amyloidosis-related conditions is a major factor behind the rising demand for therapeutic solutions. With enhanced diagnostic capabilities, healthcare professionals can now detect amyloidosis earlier, leading to a higher number of diagnosed cases and an increasing need for specialized treatments.
According to Immix Biopharma (2023), the estimated U.S. prevalence of relapsed or refractory amyloidosis cases was 29,712. Additionally, data from the Council of Health Insurance suggests that around 4,000 new cases of AL amyloidosis are diagnosed annually in the U.S., primarily affecting individuals between 50 and 65 years old, though cases have been recorded in younger adults as well.
As healthcare professionals become more adept at identifying symptoms and more patients seek treatment, the demand for innovative therapies is rising. Additionally, patient advocacy groups and research funding organizations are playing a crucial role in promoting disease awareness and driving research efforts aimed at finding more effective treatments.
Rising Investments in Research and Development (R&D) Fueling Innovation
The amyloidosis therapeutics market is benefiting from significant R&D investments by pharmaceutical companies, government institutions, and biotech firms. These investments are driving advancements in novel drug formulations, improved diagnostic tools, and personalized therapies, with an emphasis on targeting amyloidosis at the molecular level.
Recent Advancements in Amyloidosis Drug Development:
November 2024 - Intellia Therapeutics, Inc. announced positive clinical trial data for Nexiguran Ziclumeran, a one-time treatment for ATTR amyloidosis, developed as part of a collaboration with Regeneron.
December 2023 - The FDA approved WAINUA (eplontersen), a polyneuropathy treatment for hereditary transthyretin-mediated amyloidosis (hATTR-PN), developed by Ionis Pharmaceuticals, Inc. and AstraZeneca. WAINUA is notable for being the first approved self-administered amyloidosis treatment, making treatment more convenient for patients.
October 2024 - Alnylam Pharmaceuticals, Inc. submitted a supplemental New Drug Application (sNDA) for Vutrisiran, an RNA interference (RNAi) therapeutic for ATTR amyloidosis with cardiomyopathy (ATTR-CM).
The industry's focus on monoclonal antibodies (mAbs), RNAi therapeutics, and transthyretin stabilizers is expected to reshape amyloidosis treatment in the coming decade. These developments highlight the growing commitment of pharmaceutical companies to finding targeted and effective therapies.
Gain a deeper perspective by visiting our detailed report -
https://www.transparencymarketresearch.com/amyloidosis-therapeutics-market.html
Analysis of Key Players in the Amyloidosis Treatment Market
Leading companies are actively partnering with hospitals, specialty clinics, long-term care facilities, and research institutes to enhance amyloidosis drug development and expand distribution.
Key Market Players:
Pfizer Inc., Johnson & Johnson Services, Inc., GSK plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Bristol-Myers Squibb Company, Alnylam Pharmaceuticals, Inc., AstraZeneca, BridgeBio Inc., Ionis Pharmaceuticals, Attralus, Inc., Eisai Co., Ltd.
Market Segmentation and Key Growth Areas
Drug Type
Monoclonal Antibodies, Proteasome Inhibitors, Immunomodulators, Corticosteroids, Alkylating Agents, Transthyretin stabilizers, Others (RNA Interference Therapeutics, Non-Steroid Anti-inflammatory Drugs, etc.)
Indication
AL (Primary) Amyloidosis, AA (Secondary) Amyloidosis, Familial ATTR Amyloidosis
Distribution Channel
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regional Outlook: North America Leading the Market
North America dominates the amyloidosis therapeutics market, driven by advanced healthcare infrastructure, high disease awareness, and strong R&D investments. The presence of major pharmaceutical companies like Pfizer, Alnylam Pharmaceuticals, and Johnson & Johnson accelerates drug innovation, particularly in monoclonal antibodies and RNA interference (RNAi) therapeutics. Regulatory support from the FDA, including orphan drug designations and expedited approvals, further boosts market growth.
Key developments include the FDA's acceptance of Alnylam Pharmaceuticals' sNDA for Vutrisiran (November 2024) and orphan drug designation for Attralus' AT-02. Additionally, growing awareness and patient advocacy efforts improve early diagnosis and treatment adoption. Despite challenges like high costs and healthcare disparities, North America is expected to maintain its leadership through continued innovation and expanding access to advanced therapies.
Explore pivotal insights and conclusions from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86469
Future Outlook:
The amyloidosis therapeutics market is on track for robust growth, with a projected value exceeding US$ 6.3 billion by 2035. Advances in monoclonal antibodies, RNAi-based therapies, and transthyretin stabilizers will continue to shape treatment strategies, improving outcomes for patients worldwide.
As pharmaceutical companies accelerate drug development, regulatory agencies grant fast-track approvals, and patient advocacy groups drive awareness, the industry is moving toward a future of more accessible, effective, and personalized amyloidosis treatments. With continued innovation and investment, amyloidosis patients will have greater hope for improved quality of life in the years to come.
Explore Latest Research Reports by Transparency Market Research:
Heart Pumps Market - https://www.transparencymarketresearch.com/heart-pump-devices-market.html
Ingestible Sensors Market - https://www.transparencymarketresearch.com/ingestible-sensors-market.html
Ureteral Stents Market - https://www.transparencymarketresearch.com/ureteral-stents-market.html
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyloidosis Therapeutics Market Size Anticipated to Reach USD 6.3 Billion by 2034, Growing at a CAGR of 6.5% - Transparency Market Research here
News-ID: 3976511 • Views: …
More Releases from Transparency Market Research
North America Retail Work Gloves Market Eyes 11.8% CAGR Through 2031 on Back of …
The North America retail work gloves market is undergoing a significant transformation driven by industrial growth, rising occupational safety awareness, and evolving consumer preferences for comfort and durability in personal protective equipment (PPE). Work gloves, once considered mere accessories, are now recognized as essential tools in retail, construction, warehousing, and other labor-intensive sectors. The rising emphasis on workplace safety, combined with stringent regulatory guidelines across industries, has positioned retail work…
North America Residential Furnace Market Forecasted to Grow at 5.8% CAGR from 20 …
The residential furnace market in North America plays a pivotal role in the broader HVAC (Heating, Ventilation, and Air Conditioning) industry. As residential construction and home improvement projects continue to rise, furnaces have remained a staple in providing reliable and efficient heating. These systems are especially critical in regions with harsh winters such as the Northern U.S. and Canada. With consumers increasingly prioritizing energy savings and environmental responsibility, furnace manufacturers…
Home Theater Seating Market to Reach USD 3.1 Billion by 2031, Growing at a CAGR …
The global home theater seating market is witnessing consistent growth, driven by evolving consumer preferences, rising disposable incomes, and innovations in seating technology. Valued at approximately US$ 2.0 billion in 2021, the industry is poised to reach US$ 3.1 billion by 2031, expanding at a compound annual growth rate (CAGR) of 4.8% from 2022 to 2031. This comprehensive market overview delves into critical aspects of the home theater seating landscape,…
Crystal Pullers Market to Attain US$ 799.9 Million by 2034 - TMR Analysis
The Crystal Pullers Market is witnessing notable growth, fueled by the increasing demand for semiconductor devices and advanced electronic components. Crystal pullers are essential for producing high-quality silicon wafers, which serve as the foundation for integrated circuits and microchips. As industries continue to advance their digital transformation initiatives, the demand for crystal pullers is projected to rise significantly over the forecast period from 2024 to 2034.
Crystal pullers market is projected…
More Releases for Amyloidosis
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…
Amyloidosis Treatment Market Size - Forecasts to 2026
As per the research conducted by GME, the Amyloidosis Treatment Market will grow with a CAGR value of 6.8 percent. The global amyloidosis treatment market is foreseen to rise rapidly throughout the forecast period because of the increasing likelihood of amyloidosis targeted therapies releases, a growing core patient demographic since they are biologically prone to amyloidosis, surging healthcare understanding amongst individuals, and increasing disposable incomes of consumers.
Browse 151 Market Data…
New Visiongain Report: Amyloidosis Treatment Market Report 2019-2029
Amyloidosis Treatment Market Report 2019-2029
By Treatment (Stem Cell Transplant, Chemotherapy, Supportive Care, Surgery, Targeted Therapy), by Country and Segment Forecasts
Purchase full report or download free sample pages: https://www.visiongain.com/report/amyloidosis-treatment-market-report-2019-2029/
Amyloidosis is a group of rare diseases in which misfolded aggregates of protein (amyloid) accumulate in tissues and organs. The currently available amyloidosis treatments provide symptomatic relief and palliative care. These include chemotherapy, targeted therapy, supportive therapy, surgery and stem cell transplantation. High-dose…
Transthyretin Amyloidosis Treatment Market - Global Industry Analysis 2025
Transthyretin amyloidosis is a rare disease caused due to abnormal build-up of amyloidosis in the tissues of the body. The deposits of transthyretin amyloids cause illness due to damage in structure and function of the organs and moreover, they can affect any part of the body where deposits of transthyretin amyloids are present. The deposits mainly consists of abnormal, insoluble protein fibers called amyloid fibrils that are soluble in healthy…
Global Amyloidosis Therapeutics Pharmaceuticals Industry Research Report - MRH
To study the market for Amyloidosis in a precise manner, Market Research Hub (MRH) has included a new research report. The report is titled “Global Amyloidosis Therapeutics Market Research Report”, which enlightens the readers about the market share as well as growth rate during the period 2017-2022. The research study estimates that the Pharmaceutical sector would be rising with a positive CAGR during the same stated forecast period.
Request For Free…
Transthyretin Amyloidosis Treatment Market - Global Industry Insights – 2025
Transthyretin amyloidosis is a rare disease caused due to abnormal build-up of amyloidosis in the tissues of the body. The deposits of transthyretin amyloids cause illness due to damage in structure and function of the organs and moreover, they can affect any part of the body where deposits of transthyretin amyloids are present. The deposits mainly consists of abnormal, insoluble protein fibers called amyloid fibrils that are soluble in healthy…
